The Best Operating Quarter of the Year Meets the Cash Trigger We Set in July; Downgrading to Hold

Results vs. Consensus

Q3 2026 Scorecard

Consensus figures are the mid-point of independently compiled Street estimates. Core EPS estimates ranged from $2.59 to $2.62 and revenue estimates from $16.00bn to $16.03bn, so every compilation shows a beat on both lines. The operating profit, margin and Product Sales estimates come from a single compilation and are approximate.

Year-Over-Year Comparisons

The reported-to-core bridge for the quarter is $268m of restructuring, $1,188m of intangible asset amortisation and impairments, and $12m of other items, totalling $1,468m at the operating line and $0.77 per share. Total operating expense includes distribution expense.

Quarter-Over-Quarter Comparisons

Revenue

Total Revenue of $16,209m grew 7% at both constant currency and actual rates and beat a consensus of about $16.0bn by 1.3%. It follows a beat in April and a 0.4% miss in July. Sequential growth of 5.4% is the strongest of the year and comes despite the second full quarter of US Farxiga generics.

The composition repeats the July pattern. Product Sales grew 5%. Alliance Revenue, the partner-booked profit share on Enhertu, Tezspire, Datroway and Beyfortus, grew 36% to $1,107m and is now 7% of the total. That line carries almost no cost of sales, and its $292m increase supplied 29% of the $1,018m year-over-year revenue increase. US Product Sales grew only 2%, while US Total Revenue grew 5%, because two of the fastest-growing US brands, Enhertu and Tezspire, are booked by partners. Collaboration Revenue of $36m was Farxiga sales milestones.

Assessment: A clean beat at the top line with the same mix caveat as last quarter: the commercial engine the company books itself grew 5%, and the partner profit shares carried close to a third of the growth. That is not a problem, because the partnered brands are among the best in the portfolio, but it means the reported growth rate is slightly higher quality on margin than on volume.

Margins

The core operating margin of 36.1% is the highest of the year, up from 33.5% in Q2 and 35.0% in Q1, and it arrived in the quarter we expected the margin to soften. Core gross margin fell 1.7 points sequentially to 81.9%, as guided, on the seasonal mix of FluMist and Beyfortus. The whole margin gain came from operating expense: core R&D was flat sequentially at $3,645m and core SG&A fell $141m to $3,909m. Year over year, core total operating expense grew 2% against revenue growth of 7%.

"Overall, core operating expenses increased by 5% in the first 9 months. As in prior years, we expect a sequential step-up in the fourth quarter versus third quarter in operating expenses."
— Aradhana Sarin, CFO

For the nine months, core operating expense grew 5% against revenue growth of 7%, and the core operating margin was 35%, two points higher than a year ago. That nine-month figure is the better gauge of the cost line than the single quarter. Management guided a lower fourth-quarter gross margin, citing hospital budget capping and stock compensation for National Reimbursement Drug List additions in China, alongside the opex step-up.

Assessment: Our July note modelled a second-half margin that would be close to its high-water mark in Q2. Q3 proved that wrong by two and a half points. The nine-month 35% margin is the credible number and it is consistent with the operating-leverage pillar. The 36% figure will not repeat in Q4, and the forward framing of the margin on this call (taken up below) was more cautious than the number itself.

EPS

Core EPS of $2.79 grew 19% at constant currency at a core tax rate of 21%, one point below the prior-year quarter at constant currency. After two consecutive quarters in which the tax line was the largest single determinant of headline EPS, in opposite directions, this is the first quarter of 2026 in which the headline number describes the business. The core tax rate for the nine months is 19%, inside the guided 18% to 22%.

The Zoryve disposal is the one adjustment worth making. At the quarter's 21% core rate and 1,551m weighted shares it contributed about $0.05, so core EPS excluding it is about $2.74, still about 5% above consensus. Core net finance expense rose 27% at constant currency to $371m on lower interest income and higher short-term borrowing costs, and the lease on the new Kendall Square research centre adds to it from here.

Reported EPS of $2.02 grew 26% at constant currency, faster than core, because the core adjustments narrowed to $0.77 per share. Restructuring charges of $268m in the quarter already show the first costs of the new programme described below.

Assessment: The cleanest earnings quarter of the year. Core EPS for the nine months of $8.00 grew 14% at constant currency, ahead of the low-double-digit guide, and the reconfirmed full-year range now implies a decelerating fourth quarter rather than a strong one. We raise our FY2026E core EPS to about $10.30 from $10.20.

Segment Performance

Total Revenue by Therapy Area

Total Revenue by Region

Top Medicines by Product Revenue

Oncology

Oncology Total Revenue of $7,765m grew 17% at constant currency, faster than the 16% of Q1 and the 15% of Q2, and reached 48% of the company. Every one of the four largest brands grew double digits. Tagrisso crossed $2bn in a quarter for the first time at $2,087m and 12% growth, Imfinzi grew 26% to $1,990m, Calquence 16% to $1,065m and Enhertu 35% to $969m. In July we wrote that Imfinzi would overtake Tagrisso. It did not, because Tagrisso accelerated: the gap widened to $97m from $87m.

"Tagrisso delivered revenues of $2.1 billion in the third quarter, surpassing the $2 billion mark for the first time, representing 12% growth on the prior year. Demand was broad-based across indications and regions, reinforcing Tagrisso's role as the backbone of care for EGFR-mutated lung cancer."
— David Fredrickson, EVP Oncology Haematology Business Unit

Enhertu's US growth of nearly 50% came from first-line HER2-positive disease, where management said nearly four in ten patients now receive it, and the two early breast cancer indications. The softer spots were small. Lynparza fell 3%, Truqap grew only 9% because US product sales fell 10% on destocking during a switch from bottles to blister packs, and Etcamah booked $7m in its first weeks after the September US approval.

Assessment: The best oncology quarter of our coverage, and the pillar that matters most for the in-market business is stronger than at initiation. The franchise question has moved from today's numbers to the pipeline that backs them, where the quarter brought the SERENA-4 failure and the AVANZAR delay (Key Topic 3).

Cardiovascular, Renal & Metabolism

CVRM Total Revenue fell 18% to $2,639m and is now 16% of the company, down from 18% in Q2. Farxiga product revenue fell 25% to $1,605m. US Farxiga product sales were $127m, down 71% on the year against 48% in Q2. Sequentially they fell 42% from $219m, a slower fall than Q2's 51%. Emerging Markets Farxiga fell 37% at constant currency on China volume-based procurement and tender timing, while Europe grew 16%.

"Farxiga declined 23% to $1.6 billion, reflecting the loss of exclusivity in the United States and the impact of VBP in China. Demand remains strong in both Europe and established Rest of the World, both of which grew double digits."
— Ruud Dobber, EVP BioPharmaceuticals Business Unit

The new brands are small. Lokelma grew 17% to $219m, Wainua 17% to $68m, and Baxfendy booked $9m in its first full quarter on 12,000 new patient starts, almost all on commercial insurance until Medicare Part D coverage arrives in 2028.

Assessment: US Farxiga has fallen from $449m in Q1 to $127m in Q3 in two quarters of generic competition, so the US piece of this loss of exclusivity is close to fully in the run-rate. The worldwide decline will keep weighing on growth through mid-2027 as the comparison base erodes. Nothing in the quarter changes the shape of the CVRM bridge, and Baxfendy is a 2028 revenue story, as we said in July.

Respiratory & Immunology

R&I Total Revenue grew 11% to $2,518m, the same rate as Q2. The biologics did the work again: Tezspire grew 51% to $429m, Saphnelo 32% to $235m, Fasenra 14% to $602m and Breztri 14% to $374m. Symbicort fell 11% to $666m, and its US sales fell 26% after a second generic entrant.

"Tezspire maintained its impressive momentum, growing 51% to $429 million with strong performance across all regions. Growth was driven by the expanded use of biologics in severe asthma and the launch of Tezspire in chronic rhinositis with nasal polyps."
— Ruud Dobber, EVP BioPharmaceuticals Business Unit

Tezspire added a positive Phase III in eosinophilic oesophagitis, where CROSSING achieved histologic remission in 64.8% and 68.9% of patients at the two doses against 3.5% on placebo. That is a new specialty for the company, which the CFO said will require its own commercial build.

Assessment: The segment is compounding at a double-digit rate on four growing biologics while absorbing the end of Symbicort's US life. The tozorakimab filing makes R&I the segment with the largest launch in 2027, and it carries the launch spending that management says begins 18 to 24 months before a launch.

Rare Disease

Rare Disease grew 10% at constant currency to $2,633m, up from 8% in Q2. Ultomiris grew 19% to $1,432m, Strensiq 34% to $588m and Koselugo 9% to $238m, while Soliris fell 35% to $298m on conversion to Ultomiris and biosimilar pressure. Ultomiris received US accelerated approval in IgA nephropathy, and two new medicines, Klygefa in myasthenia gravis and Amlypave in AL amyloidosis, were approved in Japan.

"Our focus is on patients with higher risk of progression and inflammatory disease, which we estimate is approximately 20% of IgAN patients. IgAN is important in the continued expansion of our C5 franchise, building on Ultomiris established leadership across multiple complement-mediated diseases."
— Marc Dunoyer, CEO Alexion, AstraZeneca Rare Disease

Assessment: The re-acceleration is real and Ultomiris is carrying it. Efzimfotase alfa, the Strensiq successor, now has US priority review with a decision expected in the first half of 2027, but its adult trial missed on the overall population (Key Topic 12), which narrows the most valuable part of the label.

Infectious Disease

Infectious Disease grew 1% to $423m on the start of the respiratory season, with FluMist up 20% to $146m and Beyfortus down 2% to $233m on the partner's inventory adjustment. The segment is under 3% of revenue and seasonal.

Assessment: Immaterial to the model. The Beyfortus arbitration we flagged in July received no update in the legal note or on the call.

Key Topics & Management Commentary

Overall Management Tone: Management was more assured than in July, and the change was visible in where it spent time: the opening remarks went to the 2027 readout calendar and the post-2030 growth argument rather than to defending the portfolio after a failure. On the financial lines the tone was firmer and less forthcoming than the numbers warranted, with flat refusals on 2027 margins and on the Street's operating-margin estimates, and a margin ambition restated as defending the current level rather than expanding it. The two pipeline failures of the quarter were addressed only when an analyst raised them.

1. The cash-flow trigger we set in July has fired

Our July note named two events that would take the rating to Hold. One was a tozorakimab data set concentrated in high-eosinophil patients. The other, in our words, was "a second consecutive quarter of operating cash flow declining while accounting earnings grow." The second happened. Third-quarter operating cash inflow was $4,666m against $5,134m a year ago, a 9% decline, in a quarter where reported operating profit rose 22% and core operating profit rose 17%. On standalone quarters it is the third decline in a row: Q1 fell 10% and Q2 fell 15%.

"Cash flow from operating activities was $10.9 billion in the first 9 months, lower than in the comparative period. There are two principal factors behind that. First, the prior year period benefited from the Lynparza milestone received in Q1 2025. Second, we have experienced working capital effects associated with the U.S. loss of exclusivity for Farxiga. As previously indicated, we expect these working capital effects to persist through the remainder of the year before normalizing."
— Aradhana Sarin, CFO

The composition of the Q3 decline is narrow, and we want to state it fairly. Working capital and short-term provisions absorbed $292m in Q3 against a $835m inflow a year ago, a swing of $1,127m, while cash tax paid actually fell $61m. Trade and other payables have fallen $1.7bn since December, which is consistent with rebate and returns accruals running off as US Farxiga revenue collapses. Management flagged this in July and repeated it today. We set the trigger in July knowing that guidance, so it cannot now be the reason to set the trigger aside.

The balance sheet itself improved in the quarter. Net debt fell $1,079m to $25,833m, the capex guide was cut to a low-teens percentage increase from about one third, and management put net debt at 1.2 times EBITDA. But the $2bn Summit investment closed on 5 October and sits outside the September figure, and the quarter added two cash items that core earnings will never show: up to $2bn of restructuring that the CFO called "more a cash cost", and a $392m court judgment in the Syntimmune milestone case that the company will appeal. Deal-related payments reached $4.3bn in nine months, and they become intangible assets whose amortisation core earnings also exclude.

Assessment: The trigger fired on a cause management named in advance, and management expects that cause to reverse after year end. We are honouring it anyway, because that is what a published trigger is for. The broader point behind it still holds: for three quarters the cash statement has run behind the earnings statement, and the new restructuring programme widens the structural gap between core EPS and cash. Bear 4 moves to MATERIALIZING.

2. Tozorakimab: graded across eosinophil levels, not concentrated

The other July trigger was the largest unpriced item in the story. OBERON and TITANIA were presented at the European Respiratory Society congress in September. In former smokers, the primary population, moderate and severe exacerbations fell 29% in OBERON and 34% in TITANIA; in the overall population of current and former smokers they fell 30% and 29%. The pooled eosinophil analysis is the part we said would decide the rating.

"We saw clinically meaningful reductions in exacerbations across eosinophil levels. The reduction was 23% in patients with baseline eosinophil counts below 150 cells per microliter, 34% in those with counts of 150 or higher and 43% in those with counts of 300 or higher. Importantly, the 23% reduction was observed in a population for which no biologic is currently approved."
— Sharon Barr, EVP BioPharmaceuticals R&D

The effect is graded: it is nearly twice as large at 300 cells or more as below 150. But a 23% reduction in the low-eosinophil group, where no biologic is approved, is a real effect in the part of the population that no biologic serves today. That is not concentration. One caution came a month later: PROSPERO, the long-term extension, missed its primary endpoint of severe exacerbations in former smokers (a 21% reduction, p=0.0587) while showing a nominally significant 27% reduction in the overall population. The US filing has priority review, and management anticipates a US launch in the first quarter of 2027, subject to an approval it placed in the first half of the year.

Assessment: The trigger does not fire, and we raise our peak-year carry for tozorakimab to $3bn to $4bn from $2bn to $3bn. We stay below the company's "more than $5bn" because the effect is smallest in the low-eosinophil patients that make the label broad, because PROSPERO missed its primary endpoint, and because COPD patients sit mostly in Medicare Part D, where coverage is not expected before 2028.

3. SERENA-4 fails, and AVANZAR moves into 2027

Our July checklist named SERENA-4 and AVANZAR as the two largest oncology readouts of the second half. SERENA-4, Etcamah plus palbociclib against an aromatase inhibitor plus palbociclib in untreated advanced breast cancer, did not meet its progression-free survival endpoint, with only a numerical improvement. That was the large upfront first-line population for Etcamah. AVANZAR, Datroway in first-line lung cancer, was raised on this call as one of the six key events on the 2027 readout slide, and management did not address the change in timing.

"And I think that becomes also something that has continued growth behind it with SERENA-4 not being part of something that would cannibalize SERENA-6. Remember, SERENA-6 is the only study in a frontline advanced population."
— David Fredrickson, EVP Oncology Haematology Business Unit

The Etcamah franchise now rests on SERENA-6, the switch-on-ESR1-mutation strategy approved in the US in September, and on CAMBRIA-1 in early breast cancer next year. SERENA-6 depends on ESR1 mutation testing during first-line therapy, and management said the education work behind that testing is still under way.

Assessment: This is the quarter's most important negative, and it got less attention on the call than its size warranted. The upfront first-line indication was the volume opportunity; SERENA-6 is a narrower, test-dependent niche. Datroway's largest indication has now slipped repeatedly. Neither changes 2027 numbers much, but both reduce the oncology growth that has to replace Tagrisso in the 2030s.

4. Operating leverage: a 36% margin and a guided fourth-quarter step-up

Core operating expense of $7,704m grew 2% against revenue growth of 7% and fell 1.9% sequentially. Core R&D was 22% of revenue in the quarter and 23% for the nine months, against full-year guidance at the upper end of the low 20s. That is the source of the 36% margin and of most of the EPS beat.

"Core R&D expense increased by 5% year-to-date, reflecting continued investment in the pipeline. R&D represented 23% of total revenue in the first 9 months, and we continue to expect it to be at the upper end of the low 20s percentage range for the full year."
— Aradhana Sarin, CFO

The fourth quarter carries the usual step-up in operating expense, a lower gross margin, and higher finance costs. Ten Phase III trials of elecoglipron are now dosing, three of lenbelintide have started, and the cell therapy programme is in full Phase III, so the R&D line has real commitments behind it.

Assessment: The operating-leverage pillar had its best quarter, and nine months of core opex growing two points slower than revenue is the proof we wanted. Do not annualise the 36%. The question for 2027 is whether the leverage survives a launch year, and management chose not to answer it (Analyst Q&A).

5. Other operating income: a disposal inside it and a higher guide

Other operating income was $277m against $89m a year ago, and $618m for nine months against $281m. For the first time the company broke out one component: $100m from the disposal of the Zoryve interest. The rest, $518m for the nine months, is still a single line. The second-half guide moved up from "broadly similar" to the first half to "slightly higher".

"Other operating income was $618 million for the first 9 months, including $277 million in the third quarter. This includes the sale of Zoryve royalties for $100 million. We expect the other operating income in the second half of the year to be slightly higher than the first half."
— Aradhana Sarin, CFO

In July we said a recurring share above two thirds would restore conviction. In Q3 the recurring share was at most 64%, because the Zoryve sale was 36% of the quarter's total, and the remainder may hold further disposal gains: the release attributes the increase to royalty income and to "disposals of financial interests in mature medicines such as Zoryve", without a split. A second-half figure slightly above $341m implies a fourth quarter of at least $64m.

Assessment: The disclosure improved, and the answer it gives is the one we worried about: more than a third of the quarter's line was a sale that cannot recur, and 2027 starts with a base that includes a $100m sale that cannot recur. The conviction restorer does not trigger.

6. Reshaping for Sustainable Growth: a cash cost for capacity, not margin

The company announced a three-year programme to redeploy resources across its existing businesses, costing up to $2bn in one-time restructuring charges and delivering $1.5bn in annualised pre-tax run-rate benefits, with activities essentially complete by the end of 2029. The examples given were the clinical trial footprint, cell therapy capabilities, process development and AI embedded in non-research processes.

"This program is expected to incur up to $2 billion in onetime restructuring costs and deliver $1.5 billion in annualized pretax run rate benefits. The savings from this program will continue to be reinvested back into the company essentially in our pipeline. We expect activities to be completed by the end of 2029."
— Aradhana Sarin, CFO

Two features matter for the model. The restructuring charges are excluded from core earnings, so core EPS will not show the cost, while operating cash flow will. And the savings are reinvested, so the programme is designed to hold the cost base flat in a year with several launches, not to widen the margin.

Assessment: A sensible programme with an unhelpful accounting shape for our Bear 4 concern: about $2bn of cash leaves through a line that core EPS ignores, in return for capacity rather than profit. We assume no net core EPS benefit and treat the cost as a cash item through 2029.

7. Summit: a $2bn equity stake in the PD-1/VEGF class

AstraZeneca paid $2bn on 5 October for rights equal to about 12% of Summit Therapeutics, alongside clinical collaborations to combine ivonescimab with sone-ve and Datroway and a planned wider programme with other ADCs. In the same quarter, the Phase III eVOLVE-Lung02 trial of volrustomig, one of the company's own IO bispecifics, was stopped for futility in PD-L1-low lung cancer.

"Ivo is the leading PD-1 VEGF bispecific, a class we expect to play a role in selected tumor types. It complements our own IO bispecifics, rilvegostomig and volrustomig, which we continue to progress at pace."
— Pascal Soriot, CEO

The CFO said the fourth-quarter finance expense will include a one-time charge for the premium paid on the Summit shares, and the $2bn is not in the $2.5bn of milestone payments guided for the year.

Assessment: Strategically coherent: it buys combination access to the leading PD-1/VEGF asset while the company's own IO bispecifics, which target other pathways, have yet to report a positive Phase III, and in the same quarter one of them failed one. Financially it is $2bn of cash for a minority stake with no consolidated revenue, and on our estimate it costs about $0.05 of FY2027 core EPS in lost interest.

8. Tagrisso: combinations extend the franchise

Tagrisso grew 12% to $2,087m and 7.5% sequentially. US sales of $888m grew 13% and Europe re-accelerated to 8% at constant currency from 4% in Q2. Two Phase III data sets with Orpathys were presented at ESMO. SAFFRON, in patients with MET-driven resistance after Tagrisso, cut the risk of death by 32%. SANOVO, a China-only first-line trial in MET-overexpressed disease, extended median progression-free survival to 24.9 months from 13.8 months.

"In these patients, adding Orpathys to Tagrisso reduced the risk of death by 32% versus platinum-based chemotherapy, extending median overall survival by nearly 5 months. SAFFRON is the first global Phase III trial to show both a significant progression-free survival and overall survival benefit in this setting."
— Susan Galbraith, EVP Oncology Haematology R&D

The commercial logic is to keep patients on a Tagrisso-containing regimen after progression rather than switching them off it. The newly licensed Zegfrovy, launched in the US in October for exon 20 insertion mutations, covers a segment Tagrisso does not.

Assessment: Our July checklist asked whether US double-digit growth would hold and whether Europe would re-accelerate. Both happened. The combination data lengthens treatment duration rather than adding patients, and that is the right strategy for a franchise with a loss-of-exclusivity date ahead.

9. The 2027 bridge: known headwinds, no margin commitment

The CFO used an R&D question to set out the 2027 framework without guidance. Launches of tozorakimab, Baxfendy, Etcamah and Datroway carry investment. Farxiga and Symbicort generics continue, and Calquence enters Medicare price negotiation in 2027; the company lost its first-instance court challenge to that selection in August and has appealed.

"There are also some headwinds. Again, nothing surprising, things that you all are already aware of, generic competition in some markets and Farxiga, Symbicort, Ruud covered, Calquence goes into IRA in 2027."
— Aradhana Sarin, CFO

Calquence is a $1.1bn-a-quarter brand growing 16%, which makes it the largest single new pricing headwind of 2027. The CFO added that new biopharmaceutical launches take four or more years on average to break even, and oncology and rare disease launches about two.

Assessment: Read together with the margin answers below, 2027 looks like a year of revenue growth with a flat-to-modestly-higher margin rather than a repeat of 2026's two-point expansion. That is broadly how we model it, and it caps how far the Q3 margin can be extrapolated.

10. China returns to growth

China Total Revenue of $1,920m grew 3% at constant currency, after a 13% decline in Q2. Management said growth excluding the volume-based procurement effects on Farxiga, roxadustat and Lynparza was about 15%, and Fasenra grew strongly after its National Reimbursement Drug List listing. Emerging Markets excluding China slowed to 4% from 11% in Q2, and the release cites unfavourable Farxiga tender timing in some of those markets.

"And if you exclude for the impact of the VBP for Farxiga, roxadustat and Lynparza this year, the growth is at the level of the strong 15%. That definitely shows the strength of our current portfolio."
— Iskra Reic, EVP International

On Beijing's industrial policy, management said both the competitive pressure from domestic companies and the stronger intellectual-property protection were in its plans, and that it expects the net effect to be neutral.

Assessment: The Q2 trough was the trough, which answers the July commitment. The new soft spot is Emerging Markets outside China at 4%. One quarter of tender timing is not a trend, but it is the region the diversification pillar relied on in July.

11. Pipeline scorecard: six of nine, with caveats on both sides

Nine registrational readouts were reported since the July results. Six met their endpoints: DESTINY-Lung04 for Enhertu, DeLLphi-305 for Imfinzi with tarlatamab, MONO-OLA1 for Lynparza, SAFFRON and SANOVO for Tagrisso with Orpathys, and CROSSING for Tezspire. Three did not: SERENA-4, eVOLVE-Lung02 (stopped for futility) and AWAKE for Ultomiris in delayed graft function (stopped for lack of efficacy).

"Since our full year results in February, we've announced positive results from 12 Phase III programs, and we've achieved first approvals for 4 new medicines, including Etcamah in the U.S. This brings our total number of approved new molecular entities to 14 as we progress towards our goal of delivering 20 new medicines by 2030."
— Pascal Soriot, CEO

A 67% hit rate is above the roughly 60% aggregate probability of success the company plans on. The caveats cut both ways. MONO-OLA1 met both endpoints but will not be filed in any major market, so the commercially useful count is five of nine, or 56%. DeLLphi-305 was the strongest data set of the quarter, with a 58% reduction in the risk of death. In Europe the company also withdrew its Truqap prostate cancer application.

Assessment: Close to the base rate again, which is what the July note told us to expect. We treated a four-for-four quarter as signal in April and corrected that in July; we will not treat six of nine as signal now. Bull 1 stays AT RISK.

12. Peak-sales framing: the numbers hold while the labels move

Bear 3 tracks whether management's peak-year framings drift ahead of the evidence. The quarter added several data points. The CEO described the year's positive readouts as worth more than $10bn of non-risk-adjusted peak sales, "maintaining the scale" outlined at the start of the year; in July the CFO had called the same figure probability-adjusted, in answer to a question that recalled February's figure as risk-adjusted. The CEO's closing remarks called it "PTR revenue". Efzimfotase alfa's adult trial, HICKORY, missed its primary endpoint in the overall population because adult-onset placebo patients did better than expected, yet the $3bn to $5bn frame was restated. The eligible share of patients for sone-ve was described as about 60%, against "around 50%" in July. And cliramitug was framed at $3bn to $5bn of non-risk-adjusted peak revenue while its Phase III is still running on the strength of Phase Ib data.

"Together, these positive readouts represent more than $10 billion in nonrisk-adjusted peak year sales potential, maintaining the scale of opportunity we outlined at the start of the year. And importantly, with the positive data in hand, much of the risk behind these opportunities has now been removed."
— Pascal Soriot, CEO

The 2027 calendar was framed the same way: more than 20 high-value readouts, pivotal data for nine potential new medicines, and more than $20bn of non-risk-adjusted peak-year revenue, with about 60% of it in six key events.

Assessment: The tozorakimab data supports its framing better than we expected, and that is a point for management. But the headline $10bn figure kept its size while its basis was described three different ways in nine months, and the efzimfotase frame did not move when its adult data failed. Bear 3 stays EMERGING.

Guidance & Outlook

Implied fourth quarter: Nine-month core EPS of $8.00 grew 14% at constant currency. If "low double-digit" means 10% to 13% on FY2025's $9.16, the full year lands at $10.08 to $10.35 and the fourth quarter at $2.08 to $2.35, against roughly $2.1 a year ago. So the reconfirmed guide implies fourth-quarter core EPS growth somewhere between a small decline and 11%, which is consistent with the cost step-up, lower gross margin and higher finance charges management described. Nine-month revenue growth of 7% sits in the middle of the revenue range.

Core EPS: We set FY2026E core EPS at about $10.30, up from $10.20, which implies a fourth quarter near $2.30 and full-year growth of about 12%. The $100m Zoryve gain and the stronger third-quarter cost line explain most of the increase.

Street at: The July full-year consensus near $10.21 would need only $2.21 in the fourth quarter after this nine-month result, so we expect Street estimates to move up toward the upper half of the guided range.

Guidance style: Conservative, and visibly so. In July we read the decision not to raise at the half as a signal that the full year would land at the bottom of the band. On EPS that read was wrong: nine months at 14% put the year at or above the top of "low double-digit" unless the fourth quarter slows sharply. Management left the range unchanged with one quarter to go and said only that the fourth quarter still has to be delivered.

Grading the Commitments from Last Quarter

Our July note closed with twelve items for this quarter, and two of them carried rating consequences. This is how they scored.

Assessment: Five delivered, two partial, five that went against us or stayed silent. The scoring is less important than the two items with consequences attached. The tozorakimab test passed, so it does not move the rating. The cash-flow test failed, so it does. Neither conviction restorer from July triggered: the recurring share of other operating income stayed below two thirds, and guidance was not raised at nine months. There is nothing on the other side of the ledger to net against the trigger.

Analyst Q&A Highlights

Whether the year's readouts added value net of the two failures

The most direct question of the call asked whether the year's pipeline outcome was positive or negative in value terms once the two high-profile failures are counted. Management answered with an unambiguous yes and gave two reasons the failures cost less than they appear to, and it put a number on the low probability of success it had assigned to tozorakimab.

Q: "I think the market's arguably focused more on 2 failures, Wainua and SERENA-4. So on your internal estimates, if you were actually looking at the risk-adjusted NPV of those readouts that you're expecting as you went through the course of the year, is your projection now that internally you think the value of those has gone up rather than down on aggregate through the course of the year?"
— Graham Parry, Citi

A: "And there's no doubt actually, Graham, that if we look at it in net NPV, if you want, we've gone up net-net of the 2 failed studies, Wainua and also SERENA-4. And let me tell you why. First of all, it's important to remember, Wainua is a shared product. So we didn't own 100% of the profitability coming out of it. The second is, of course, SERENA-4 was a large opportunity, but some of that opportunity is replaced by SERENA-6."
— Pascal Soriot, CEO

Assessment: The answer is plausible, and the disclosure that tozorakimab carried only a 20% to 25% probability of success in the company's forecast explains it: a low-probability asset turning positive adds more value than a high-probability asset failing removes. The weaker part is SERENA-6 as a replacement for SERENA-4. One is a niche defined by a mutation test, the other was the first-line market.

Whether the 2027 readout slide rests on a single asset

The 2027 calendar carries more than $20bn of non-risk-adjusted peak revenue, and the question asked whether Datroway's AVANZAR trial accounts for a disproportionate share. Management said no, listed other contributors, and returned to the 60% aggregate probability of success it uses in its plans.

Q: "So firstly, with regards to the Slide 24 and the $20 billion -- more than $20 billion non-risk-adjusted peak year revenue potential, and 60% of that value derived from the 6 key events to the left on that slide, is it fair to distribute the peak revenue broadly average across the 6 key readouts? Or is it rather so that perhaps some AVANZAR carry an unproportional component of those $12 billion peak year revenue?"
— Mattias Häggblom, Nordea

A: "So Datroway is going to play an important role, but it's not the one that is going to be a make or break. We have a risk-adjusted approach in our forecast. And when we say that we can grow through 2030 and beyond. And as I've said before, our risk adjustment across the totality of the portfolio, about 60%. So it's not very ambitious. We've done much better than that in the past."
— Pascal Soriot, CEO

Assessment: The answer did not engage with the distribution. It also gave no explanation of why AVANZAR, guided to the second half of 2026, now sits on the 2027 slide. The 60% planning assumption is the right frame, and it is also the reason one quarter's hit rate should not move the multiple in either direction.

What the restructuring programme is, and whether it is cash

The first question on the new programme asked what it is and whether the $2bn is cash. The answer described a set of smaller initiatives rather than one large one, and confirmed the cash character of the cost.

Q: "I wonder if you could give us a little bit more color on the Reshaping for Growth strategy. I would assume that this is a transfer of OpEx from SG&A to R&D. But any color you can give us there would be great. And also, is the $2 billion a cash cost? Or is it a mix of cash and noncash?"
— Simon Baker, Rothschild

A: "So those are the types of things that -- again, there's not one major thing. There's many different smaller initiatives. The $2 billion is more a cash cost. The benefits are -- again, it's a 3.5-year program. So it's not sort of a onetime thing. The costs will come over this longer-term period as will the benefits."
— Aradhana Sarin, CFO

Assessment: "More a cash cost" settles the question that matters for Bear 4. A later question on timing got the answer that the plan has been in preparation since the start of the year, prompted by the Farxiga loss of exclusivity, the readouts and the use of AI in non-research processes. No annual phasing of the cost was offered.

Whether 2027 R&D growth caps the Street's margin expansion

A modelling question tied consensus R&D growth of about 5% for 2027 to the roughly 100 basis points of margin expansion the Street carries, and asked whether the new Phase III starts change both. The CFO declined to guide and listed the headwinds instead.

Q: "R&D growth year-to-date sort of 5%, which is also what consensus assumes for '27. A lot of what we've heard today is a lot of new Phase III starts. So very simply thinking, do we think about R&D growth accelerating next year and how that impacts the extent of margin expansion, which currently stands at about 100 basis points in consensus?"
— Sachin Jain, Bank of America

A: "There are also some headwinds. Again, nothing surprising, things that you all are already aware of, generic competition in some markets and Farxiga, Symbicort, Ruud covered, Calquence goes into IRA in 2027. Again, all the things that are very -- you're all very well aware of. We'll continue to invest in R&D and focus remains on executing and building the pipeline, and we will share our guidance when we get to February of next year."
— Aradhana Sarin, CFO

Assessment: The CFO chose to answer a margin question by listing headwinds and launch investment, and did not offer the 100 basis points any support. We read it as a soft warning against extrapolating the 2026 margin expansion.

Whether the investment programme leaves room for margin expansion

The broadest version of the margin question asked whether the restructuring and top-line growth exist to hold margins while the new platforms are funded, or whether the margin can still expand. The CEO's answer moved the margin language from expansion to protection.

Q: "So if we put it all together, is the message that the cost reallocation program and the top line growth would be there to keep the margins above flat whilst you do all this investment? Or can you do all this investment and also have margin expansion medium, long term?"
— James Gordon, Barclays

A: "But we believe that we can actually balance the P&L. It is, of course, never easy when you have a pipeline of that magnitude. It's a great problem to have. We have many, many projects, but we will continue investing in those and of course, try to defend and protect our operating margin."
— Pascal Soriot, CEO

Assessment: "Defend and protect" is not the language of a company planning further expansion. The CFO added that the investor-day commitment was to the 2026 margin and that the margin beyond it would depend on scenarios. On a quarter with a 36% margin, management chose to lower expectations rather than raise them.

Whether the restructuring savings reach the margin at all

A follow-up asked directly whether the savings would be recycled into R&D and whether management was comfortable with the Street's operating margin for the next two years. The first half got a yes. The second got a refusal.

Q: "So Aradhana, just hoping you could clarify and help us think about the impact that the restructuring program could have on margins going forward. Is this going to be kind of fully sort of recycled back into R&D? And then as we just sort of think about the margin structure, are you comfortable with where the Street is for the next couple of years as it relates to operating margins?"
— Seamus Fernandez, Guggenheim

A: "So the answer to, I think, your first question is yes, though we will look to reinvest. And again, it's not just about reinvesting, it's also, like I said, creating the capacity to do more without expanding our cost base as much. ... Your second question, I won't go into, though I know everybody is very creative in asking the same question. We will not provide long-term margin guidance in spite of many ways and creativity in asking that question."
— Aradhana Sarin, CFO

Assessment: Three margin questions, three answers that declined to endorse expansion. The programme is about capacity, and its benefit shows up as a slower-growing cost base in a launch-heavy period, not as a wider margin. We do not model any net core benefit from it.

How far the Orpathys combinations extend Tagrisso

The Tagrisso question asked how much SAFFRON and SANOVO add, and what the Datroway combinations could bring beyond them. The answer described a sequence of Tagrisso-based regimens from first line through progression.

Q: "But just how we should think about the performance going forward, potential from the uplift from SAFFRON and SANOVO that was called out today in at ESMO. And actually thinking further beyond that, just what could the combinations with Datroway, TL15 bring to that franchise as well?"
— Richard Vosser, JPMorgan

A: "So Tagrisso, with 8% sequential growth, I think, is performing very well. And that strength is really coming on the back of a lot of good work that we're doing to establish FLAURA2 as the preferred regimen in frontline for patients with EGFR mutated disease."
— David Fredrickson, EVP Oncology Haematology Business Unit

Assessment: The answer framed the combinations as a way to keep patients on Tagrisso for longer, through first-line combinations and Tagrisso-containing regimens after progression. That supports duration and price rather than a larger population, and it is the right defence for a mature franchise.

What the new launches contribute in 2027

The launch question asked how meaningful Baxfendy, Etcamah and tozorakimab will be to 2027 revenue. The answer gave the first hard Baxfendy data point and set out why both cardiovascular and respiratory launches wait on Medicare Part D.

Q: "You've obviously got Baxfendy and Etcamah this year and tozorakimab potentially next year if it's approved. Could you just maybe talk about how meaningful they will be from a revenue perspective next year in terms of drivers of growth?"
— Rajan Sharma, Goldman Sachs

A: "We have already been able to deliver 12,000 new patient starts. As expected, most of those patient starts are in the commercial book of business because we don't have any coverage yet in Part D, and that will take some time. It's not unusual. We have submitted our bids for Part D to all the plans. And hopefully, we will see the coverage in 2028 coming through."
— Ruud Dobber, EVP BioPharmaceuticals Business Unit

Assessment: Twelve thousand new patient starts on $9m of revenue is a normal early-access profile. The useful addition was on tozorakimab: a prefilled syringe for Medicare Part B and an auto-injector for Part D, because COPD patients skew to Part D. Both launches are 2028 revenue stories, and the CFO's four-plus-year break-even for biopharmaceutical launches puts their profit contribution later still.

What They're NOT Saying

1. Why AVANZAR moved. Guided to the second half of 2026, it came up on this call only when an analyst asked about the 2027 readout slide. Neither the release nor the prepared remarks mention the trial or explain the timing, and it is Datroway's largest indication.
2. The annual phasing of the restructuring cost. The release and the call give the total (up to $2bn), the benefit ($1.5bn annualised) and the end date (2029). How much cash goes out in 2027 and 2028 was not given, and that phasing decides whether operating cash flow can catch up with earnings next year.
3. The size of the Summit premium charge. The CFO said fourth-quarter finance expense will include a one-time charge for the premium paid. The amount, and whether it sits in core finance expense, were not given. It falls inside the quarter the reconfirmed guide already needs to slow.
4. The rest of other operating income. Zoryve is now broken out. The remaining $518m for nine months, up 84% on a year ago, has no split between royalties, milestones and further disposal gains, and the guide for the second half was raised regardless.
5. When the working-capital drag reverses, and by how much. Management repeated that the effects persist through year-end "before normalizing". It gave no size for the reversal and no quarter for it, and the cash trigger in this note depends on both.
6. The Syntimmune judgment. A $392m judgment entered in October is disclosed in the legal note, with an intention to appeal. It was not mentioned on the call.
7. The respiratory biologics False Claims Act suit. The legal note discloses a qui tam lawsuit, unsealed and served in October, that alleges unlawful promotion of Fasenra and Tezspire. Those two brands grew 14% and 51% this quarter. The suit was not mentioned on the call.
8. The failed trials that were not on the agenda. eVOLVE-Lung02, a Phase III of the company's own PD-1/CTLA-4 bispecific, was stopped for futility in August; PROSPERO missed its primary endpoint; HICKORY missed in the overall adult population; and the Truqap prostate application was withdrawn in Europe. All four are in the release, and none of the four setbacks was discussed in prepared remarks or Q&A.
9. A consistent basis for the "more than $10bn" figure. The year's positive readouts were described as non-risk-adjusted peak sales in the opening remarks and as "PTR revenue" in the closing remarks, after a probability-adjusted description in July. The number stayed the same while its basis changed.

Market Reaction

• Pre-print setup: The shares closed at $174.40 on 29 October, down 0.6% year to date against the S&P 500's 12.8% gain, up 5.9% over the trailing twelve months and up 8.0% over the trailing thirty days. The 52-week closing range entering the print was $155.62 to $209.48, placing the shares about 17% below the high.
• Print-day session: Results were released at 07:00 UK time, before the US open, and the call began at 14:30 UK time, or 10:30 ET. The shares opened at $183.59, a 5.3% gap higher, traded a $183.10 to $188.39 range, and closed at $186.65, up 7.0% or $12.25.
• Volume: 5.5 million shares against a 2.9 million thirty-day average, 1.9 times normal.
• Market context: The S&P 500 fell 1.8% on the session, so the move was about 8.8 points better than the market and entirely idiosyncratic.

This is the first print of our coverage that the stock reacted to. April delivered four positive Phase III programmes and the shares fell 0.8% on 2.4 times normal volume. July delivered a tax-driven beat and a mixed pipeline and the shares rose 0.2%. October delivered an operating beat with a 36% margin and a new restructuring programme, and the shares rose 7.0% against a falling market. The market had spent two quarters pricing this name on policy risk and the 2032 patent cliff; this session it priced the earnings.

The shape of the session says the release did the work, not the call. Most of the move was in place at the open, an hour before the call started, and the close at $186.65 held most of the gain to the $188.39 high. The margin beat and the $1.5bn savings headline were in the release; the call's caution on 2027 margins and its silence on AVANZAR did not take much back.

The move also changes our arithmetic. At $186.65 the shares are back within 1% of the $185.20 close at our April initiation, after falling as far as the mid-$150s within the past year. The 10.0% gain since our July note is roughly the upside we then saw to a $200 target, and most of it arrived in one session.

Street Perspective

Debate: Is the 36% margin a run-rate or a phasing quarter?

Bull view: Core operating expense grew 2% against 7% revenue growth, the nine-month margin is 35% and two points higher year on year, and the company has delivered the margin it promised at its investor day. A business with this revenue mix should hold the mid-30s, and the 2027 margin estimates on the Street look low.

Bear view: The quarter had a $100m disposal in other operating income, a sequential fall in opex that management itself said reverses in Q4, and a seasonal gross margin trough still to come. Asked three times about margins, management offered "defend and protect", and 2027 adds Calquence price negotiation and a launch year.

Our take: The nine-month 35% is the right base and the 36% is a phasing quarter. The bear camp has the better read on 2027, because the company's own language moved from expansion to protection on the day it printed its best margin.

Debate: Does the restructuring programme create margin or only capacity?

Bull view: $1.5bn of annualised savings is about 2% of revenue at the 2030 ambition, and even if it is reinvested it lets the company fund three or four launches and a cell-therapy build without the cost line outrunning revenue. That protects the margin through the loss-of-exclusivity cycle.

Bear view: The company told investors the savings are reinvested and gave no margin guidance, so the only certain effect is up to $2bn of cash restructuring that core earnings exclude. It arrives in the same period as rising capex, a $2bn equity stake and three quarters of falling operating cash flow.

Our take: Both sides describe the same programme accurately. We side with the bear view on the accounting and the bull view on the strategy: the programme is sensible, and it makes core EPS a less complete measure of the cash this business generates.

Debate: Did the pipeline improve or deteriorate this quarter?

Bull view: Tozorakimab showed a 23% exacerbation reduction in a low-eosinophil population with no approved biologic, DeLLphi-305 cut the risk of death by 58%, and six of nine registrational readouts hit. Management says the net value of the year's readouts rose even after the two failures.

Bear view: The largest oncology readout of the half failed, the largest Datroway trial slipped again, a bispecific Phase III was stopped for futility, the efzimfotase adult trial missed, and one of the six wins will not be filed. The peak-sales frames did not move for any of it.

Our take: Net neutral to slightly positive. Tozorakimab was the item with the most value at stake and it came through. SERENA-4 matters more for the 2030s than for the 2027 numbers. A conversion rate near the 60% plan is what a portfolio this size should produce.

Debate: After the rally, is the de-rating over?

Bull view: At 16.7 times FY2027E core earnings the shares trade at about their April multiple, on a higher FY2026 base and a stronger operating trajectory. A clean beat with the tax noise gone should start a re-rating toward the large-cap pharmaceutical premium.

Bear view: The shares have recovered 10% in three months and 7% in one session, and they now sit back at the April price, before CARDIO-TTRansform and SERENA-4 failed. The policy overhang, the 2032 patent cohort and the cash conversion gap are all unchanged.

Our take: The de-rating that made the shares cheap in July has largely reversed. At 16.7 times our unchanged FY2027E, against 15.1 times in July, the price now reflects most of the operating improvement and leaves a total return close to the market's. That is a Hold.

Model Update & Valuation Framework

Valuation. At the 30 October close of $186.65, the shares trade at about 18.1 times our FY2026E core EPS of $10.30 and 16.7 times our FY2027E of $11.20. In July, on the same FY2027E, they traded at 15.1 times. The whole of the move is in the multiple: our FY2027E is unchanged, so the 10.0% price gain since the July note is a 1.5-turn re-rating. The shares are now within 1% of the $185.20 close at our April initiation, and on an unchanged FY2027E they trade at about the same multiple.

Price target: $200, unchanged. That is about 17.9 times our FY2027E core EPS of $11.20 and implies 7.2% upside from $186.65. With the 2026 dividend of $3.30, a yield of about 1.8%, the expected total return is about 9%, which is close to what we expect from the market. We do not raise the multiple. Pipeline conversion is back near the base rate rather than above it, the cash statement has run behind earnings for three quarters, and management declined to support margin expansion in 2027.

Bear case, $168. Fifteen times FY2027E, about 10% below the current price. This is the case where the working-capital drag and restructuring cash keep operating cash flow below earnings into 2027, the 2027 guide implies a flat margin, and the policy overhang persists.

Bull case, $232. Twenty times an FY2027E lifted toward $11.60 by a strong tozorakimab launch, operating leverage that survives the launch year, and the six key 2027 readouts converting above plan. About 24% above the current price.

Why Hold and not Underperform. The operating business is in better shape than at any point in our coverage: the cleanest earnings quarter of the year, oncology at 17%, China back to growth, and the tozorakimab data cleared the test we set. The downgrade comes from our own published trigger and from the price, not from a deterioration in the franchise. A business compounding core EPS at about 10% with a 7% upside to our target is a market performer.

What would change our mind. We would return to Outperform on either of two conditions. First, operating cash flow growing at least as fast as core operating profit for two consecutive quarters. Management says the working-capital effect normalises after year end, but our base case assumes the restructuring cash keeps the gap open through most of 2027. Second, a pullback to about $170 or below without a cut to FY2027E, which would restore the upside we saw in July. We would move to Underperform if the February 2027 guide implies core EPS growth below mid-single digits, or if two or more of the six key 2027 readouts fail. If the shares fall toward $170 and the February guide disappoints in the same period, the two signals offset and we would stay at Hold.

Thesis Scorecard Post-Earnings

Overall: Mixed, and the rating follows our published rule rather than the balance of the quarter. The three operating pillars had their best quarter of our coverage, and the largest unpriced pipeline item came through. The cash pillar moved the wrong way for a third quarter, with a new programme that will widen the gap between core earnings and cash through 2029. The price has also done much of what we expected it to do over twelve months. The thesis that this is a well-run pipeline-conversion business stands. The thesis that it is mispriced is weaker at $186.65 than it was at $169.64.

Action: Hold. Do not add at this price, and trim positions added near the July price. The next decision point is the February 2027 results, where the fourth-quarter cash flow, the restructuring phasing and the 2027 margin guide will show whether core earnings and cash converge again. After that, the six key 2027 readouts take over.